Rite Aid gets court approval for $575 million Elixir sale
Reuters
Published Jan 09, 2024 12:12PM ET
Updated Jan 09, 2024 03:02PM ET
By Dietrich Knauth
NEW YORK (Reuters) - Pharmacy chain Rite Aid (NYSE:US90274J5618=UBSS) Corp on Tuesday received bankruptcy court approval to sell its Elixir pharmacy benefit manager business for $575 million.
Rite Aid filed for bankruptcy in October with an agreement to sell the Elixir business to pharmacy benefit manager (PBM) MedImpact Healthcare Systems for that price.
The company continued to shop Elixir to more than 30 potential buyers during its bankruptcy, but no bidder offered a higher price than MedImpact's initial offer, Rite Aid attorney Ross Fiedler said on Tuesday at a bankruptcy court hearing in Trenton, New Jersey.
Fiedler said the Elixir sale is a critical part of Rite Aid's effort to raise money and re-focus on its retail pharmacy business in bankruptcy.
He told U.S. Bankruptcy Judge Michael Kaplan, who is overseeing the company's Chapter 11 proceedings, that the sale will likely close within the first quarter of 2024.
Kaplan approved the sale during the court hearing.
Rite Aid, one of the largest U.S. pharmacy retailers, cited its high debt, revenue declines, increased competition, and opioid litigation as factors that caused its bankruptcy.
Rite Aid closed 200 stores before its bankruptcy, and has continued to close more stores as its Chapter 11 case proceeds.
PBMs negotiate drug prices and rebates with drugmakers on behalf of employers, health plans and other clients.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.